started · updated
Longevity science shifts focus from lifespan to healthspan
Longevity science is shifting focus from merely extending lifespan to increasing healthspan—the period of life spent in good health. Researchers are increasingly viewing aging as a malleable biological process rather than an inevitable decline. This shift is driven by breakthroughs in gene therapy, cellular reprogramming, and the development of senolytic therapies designed to eliminate senescent cells.
Artificial intelligence is playing a critical role in accelerating this research by analyzing vast genomic datasets and identifying existing drugs that can be repurposed to target the hallmarks of aging. The global longevity market is projected to exceed $600 billion by the end of the decade.
A study of Swedish health records by the Max Planck Institute for Demographic Research and the Karolinska Institute highlights how medical progress is reshaping the diseases experienced in old age. While improved treatments allow patients to survive longer with certain conditions, such as cardiovascular diseases, advancements in prevention are reducing the incidence of others.
Entities
FDA · Karolinska Institute · Max Planck Institute for Demographic Research
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] Researchers from the Max Planck Institute for Demographic Research and Karolinska Institute analyzed Swedish health records from 1987 to 2022. knowridge.com
- [○ 1 SOURCE] Artificial intelligence is accelerating longevity research by analyzing genomic datasets and predicting drug repurposing.
- [○ 1 SOURCE] The study examined health data for individuals born between 1904 and 1960. knowridge.com
- [○ 1 SOURCE] The global longevity market is projected to surpass $600 billion by 2030.